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S U M M A R Y
Vagal nerve stimulation (VNS) has shown promising results in various cohorts of non-surgical refractory
epilepsy in adults and children. However studies report a signiﬁcant delay between implantation and
clinical response. We describe a cohort of 28 children and adolescents prospectively followed, classiﬁed
by epileptic syndromes and treated with VNS using a 6-week rapid ramping protocol between January
2000 andMarch 2005. Our cohort showed favorable outcomewithin 6months whichwas sustained at 24
months: 68% (19/28) showing 50% reduction in seizure frequency, including 14% (4/28) who became
seizure-free. VNS was particularly efﬁcacious in children with cryptogenic generalized and partial
epilepsies. Although adverse events occurred in 68% (19/28) of patients, most were transient. In
conclusion, rapid ramping is associated with an early and lasting response in most children but with a
slightly higher side-effect rate.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
journa l homepage: www.e lsev ier .com/ locate /yse izIntroduction
Vagus nerve stimulation (VNS) has shown promising results in
various cohorts of non-surgical refractory epilepsy in adults and
children. We enrolled the ﬁrst 28 children and adolescents treated
with VNS in our institution in a protocol designed to assess the
efﬁcacy and optimal use of VNS in children with refractory epilepsy
classiﬁed by epileptic syndromes. As most children were experien-
cing multiple seizures per day, we developed a 6-week rapid
ramping protocol. Their medication was not modiﬁed for the ﬁrst 6
months of therapy. We report the outcome at the 6 and 24 months
follow-up visits.
Methods
All patients treatedwith VNS at our institution between January
2000 and December 2004 were included in this study. All patients
and their caregiver were required to keep a detailed seizure diary 2
months prior to implantation and for the ensuing follow-up period.
Baseline investigations consisted of video-EEG monitoring, cere-
bral magnetic resonance imaging and functional imaging studies
to exclude the presence of a surgically removable epileptic focus.
Neuropsychological evaluation was obtained prior to VNS in all
patients, and 6 months after initiation of VNS in the ﬁrst 16* Corresponding author at: Ste-Justine Hospital, Neurology Division, 5e`me Bloc 4,
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months, after which they could be adjusted as necessary by the
treating neurologist.
Visits were performed weekly for the ﬁrst 6 weeks to increase
stimulus intensity from 0.25 mA set at the time of surgery to
1.5 mA, then monthly up to 6 months and as needed over the next
18 months. At each visit, a new seizure diary was given to the
parents in order to document the evolution of each type of seizures.
EEGs were performed at 6 and 24 months follow-up and when
increased seizure frequency or apparition of new seizure types
were noted. EEG recordings were obtained on Stellate EEG
machines and traces were analyzed using Stellate Harmonie
Software (Mtl, Canada). Side effects were recorded throughout the
follow-up period.
Results
Baseline data and epilepsy classiﬁcation (Table 1)
Patientswere agedbetween2months and7 years oldwhen their
epilepsy was diagnosed. We treated 13 males and 15 females.
Speciﬁc epileptic syndromes were diagnosed when possible. There
were three generalized idiopathic epilepsies with absence seizures,
ﬁve Lennox-Gastaut syndrome, two severe infantile myoclonic
epilepsyofDravet,onemyoclonicepilepsyofDoose,ﬁvecryptogenic
generalizedepilepsies, seven cryptogenic bilateral partial epilepsies,
and ﬁve partial symptomatic epilepsies (two bi-frontal and three
bilateral independent).1 No child had an underlying metabolic
disorder.vier Ltd. All rights reserved.
Table 1
Baseline data and post-VNS seizure reduction at 6 and 24 months
Pt Sex Dx Onset Previous tx Sz-type 6 months 2 years Maximal seizure effect
1 M GI-abs 2 years D A Sz-free Sz-free A
2 F GI-abs 5 years A, GTC Ø Ø GTC
3 F GI-abs 7 years D A, M # 50% # 50% M
4 F GS-LG 4 months D GTC, At, M, T, AtyA # 50% # 50% M
5 F GI-LG 2 (1/2) years D PC, T # 50% # 50% T
6 M GS-LG 1 (1/2) years D, call GTC, PC Ø Ø No effect
7 M GI-LG 3 years AtyA, M, A # >90% Sz-free Sz-free
8 M GS-LG 4 years At, M, T, GTC, AtyA Ø Ø M
9 M GC-SMEN 5 months D GTCS, AtyA, M # >90% # >90% M
10 M GI-SMEN 6 months D GTC, M Ø Ø GTC
11 F GI-Doose 2 years D AtyA, At, M # >90% Sz-free M
12 M GC-m 5 months D AtyA, At, M, PC # 50% # >90% M
13 M GC-m 7 months Lob T, PC, GTC # >90% # >90% T
14 F GI-m 13 months D M, At, PC, GTC # 75% # 75% PC
15 F GC-m 18 months D AtyA, M # 75% Ø No effect
16 M GC-m 2 (1/2) years M, GTC, PC # 25% # 25% PC
17 F PC (F) 4 months D GTC, PC, M # 50% # 50% M
18 M PC (F) 2 years D PC # 75% Sz-free x 1 y Sz-free
19 M PC (F) 2 (1/2) years PC Ø # >90% PC
20 F PC (F) 3 years D T, At # 75% # 75% At
21 F PS (F) 4 years Call At, M # 50% Ø M
22 M PC (F) 1 years D PC # >90% # >90% PC
23 F PS (FT) 3 (1/2) years D PC # 50% # 50% PC
24 F PC 2 months A, PC, At # 50% Ø No effect
25 F PC 2 months D PC # >90% # >90% PC
26 F PS 6 months PC # >90% Ø No effect
27 F PS 4(1/2) years PC, GTC, M # >90% # >90% PC
28 M PS 6 years PC, T Ø # >90% PC
GI, generalized idiopathic epilepsy; GS, generalized symptomatic epilepsy; GC, generalized cryptogenic epilepsy; GI-abs, generalized absence epilepsy; LG, Lennox-Gastaut;
SMEN, severe myoclonic epilepsy newborn; PC, partial cryptogenic epilepsy; PS, partial symptomatic epilepsy; D, ketogenic diet; A, absence; AtyA, atypical absence; GTC,
generalized tonico-clonic; M, myoclonic; T, tonic; At, atonic; PC, partial complexes; call, callosotomy; lob, partial lobectomy.
E. Rossignol et al. / Seizure 18 (2009) 34–37 35Before initiation of VNS, patients had received 3–13 medica-
tions at therapeutic levels (mean of 9 medications per child). The
ketogenic diet had failed in 18 patients. The other patients
were deemed unsuitable for ketogenic diet therapy due to
medical or nutritional problems. In addition, three patients had
failed prior surgical treatment: two callosotomies, and one
frontal lobectomy.
Pre-implantation cognitive functional level
All patients had a neuropsychological evaluation prior to VNS
initiation and all, except those with idiopathic generalized absence
epilepsy, were cognitively impaired. They were classiﬁed as
suffering from severe mental retardation (21%: 6/28), moderate
mental retardation (39%: 11/28), or mild mental retardation (29%:
8/28) as assessed with the Bayley scales of infant development or
theWechsler’s pre-school and primary scale of intelligence (WIPSI
III) with mild mental retardation deﬁned as IQ 55–70, moderate IQ
40–55 and severe IQ < 40.
Effects of VNS on seizure type, epileptic syndrome, and EEG changes
(Table 1 and Supplemental Table 1)
Patients were between 3 (1/2) and 21 years old when VNS
therapy was initiated, the older patient being a severely disabled
child with Lennox-Gastaut syndrome. The mean delay between
diagnosis of epilepsy and VNS therapy was 7 years (range: 2–17
years). All but four patients completed the 24 months follow-up
period.
At 6 months, seizures were reduced by >50% in 21/28 children
(75%). At 24months of follow-up, this favorable outcome persisted
in 68% of our patients (19/28) (Fig. 1). Six responders showed an
additional improvement after 6 months. These changes in seizure
control were not related to speciﬁc changes in seizure medication.In contrast, four patients who had an initial response at 6 months
lost seizure control at 24 months.
At 2 years, themean seizure reduction rate was 53% per patient.
In our population, seizures that were the most responsive to VNS
therapy included atonic (86% > 50% reduction), tonic (100% > 50%
reduction) and myoclonic seizures (75% > 50% reduction) (Fig. 2).
Those seizures are frequently seen in patients with refractory
generalized epileptic syndromes. For instance, in children with
Lenox-Gastaut syndrome, 3/5 patients showed 50% seizure
reduction and a fourth had his generalized tonico-clonic seizures
and tonic seizures controlled but with the persistence of atypical
absence seizures. Our patient with Doose syndrome became
seizure-free at 2 years. The other generalized epilepsies with
myoclonic seizures had a good response to VNS with 60% (3/5)
showing 75% seizure reduction, while two showed no or mild
responses. Of the two patients with Dravet syndrome, one had 90%
seizure reduction while the other had no response. But partial
epilepsies also responded very well to treatment with 9 patients
out of 12 showing signiﬁcant improvement: 1 with 50% reduction,
1 with 75% reduction, 6 with 90% reduction and 1 becoming
seizure-free.
Three patients had previous epilepsy surgery and their results
were comparable to that of other children.
The analysis of post-VNS EEG in our patients did not show
consistent modiﬁcations of ictal or interictal EEG patterns at 6 or
24 months.
Medication modiﬁcations following VNS
28% (8/28) patients remained on the same medications
throughout follow-up. We were able to decrease the therapeutic
regimen in only 14% of children (4/28). One patient was free of
medication at follow-up. In 57% (16/28), one anticonvulsant was
tapered but replaced by a new medication.
Figure 1. Global effect on seizure frequency.
E. Rossignol et al. / Seizure 18 (2009) 34–3736Effects of VNS on cognitive functions, behavior and quality of life
No change in level of cognitive functioning was observed
between baseline and 6-month evaluations in 16 children tested at
both time-points. However, in 69% (11/16) of our patients the
neuropsychologist reported improvement in alertness, playfulness
and global interaction, and 93% (26/28) the caregivers reported
improved nigh time sleep.
Side-effects and adverse outcomes
68% (19/28) of our patients experienced one or more side
effects. Most children complained of minor adverse events such as
throat pain, voice change, chest discomfort, local thoracic pain at
site of VNS battery, dyspnea, coughing or mild dysphagia which
were either transitory or tolerable.
Two patients (#11, 17) had severe discomfort at the site of VNS
battery and necessitated surgical repositioning. Deep infection
required VNS removal and antibiotic treatments in two patientsFigure 2. Effectivenes(#3, 26). For these four patients, VNS was reinstituted within few
weeks with similar beneﬁts as recorded prior to removal. Two
patients were considered as drop-outs and recorded as failure of
VNS therapy (no signiﬁcant impact on seizure frequency): one
child complained of severe dysphagia requiring removal of the
device (#8), and a severely disabled child (#6) died from upper
airway obstruction when hewas left unattended eating solid foods
two months following initiation of VNS.
Discussion
Effect of VNS on seizure frequency
VNS studies in adults have shown a mean seizure reduction of
49–64% at 2 years, with 43–75% of patients showing 50%
reduction in seizure frequency. Results in pediatric studies have
beenmore variable. Mean seizure reduction varies between 42 and
58%, but follow-up has often been limited to 6–18 months.2–14
Percentages of patients showing >50% reduction in seizure
frequency vary between 37 and 75%, with 5–18% of patients
becoming seizure-free. Our results are in the upper range of
pediatric studies. Response rate was higher at 6 months with our
protocol.
The results in our small cohort conﬁrm previously reported
efﬁcacy in Lennox-Gastaut syndrome.2,7,8,12,15 In addition, we
demonstrate similar efﬁcacy in other cryptogenic generalized and
partial epilepsies. Regarding seizure type, generalized tonic clonic
seizures appear to be themost refractory to VNS therapy. However,
we demonstrate particular efﬁcacy of VNS against seizures
potentially associated with falls and injuries.
Side effects
Side effects occurred in 68% of our patients, andmost weremild
or transient. This is elevated compared to other pediatric studies. Ins by seizure type.
E. Rossignol et al. / Seizure 18 (2009) 34–37 37a review of adverse effects in children treated with VNS, Murphy
et al. reported 15 adverse events in 12 patients out of 24 patients.16
Mild adverse events such as throat discomfort and hoarseness are
frequently reported in the immediate post-implantation period
(30 and 60% of patients, respectively) but tend to diminish with
time as in our cohort, reaching 4.7 and 18.7% at 5 years.17
By comparison, six of our patients experienced severe side
effects including two infections requiring removal of the implant
and antibiotic treatment, with subsequent reimplantation of VNS,
two severe discomforts at the site of the battery requiring surgical
repositioning, and two cases of severe dysphagia. In the cases
where VNS was reimplanted, therapeutic effects were comparable
following reimplantation as prior to removal. We have not
experienced a signiﬁcant complication during surgical procedures
and these side effects were thus considered severe but amendable
to therapy. Infections at the site of implants have been reported in
the literature as affecting 3–11% of patients in other series. It has
been suggested that most of these infections may be treated by
antibiotics alone and do not necessitate removal of the device.18
Cases of severe dysphagia with VNS therapy have been previously
reported, and this may in some cases lead to aspiration pneumonia
as reported by Lundgren et al.19 In our cohort, the unfortunate
death of patient #6 could not be clearly attributed to VNS as the
child was left unsupervised with solid food.
Behavior, cognition and quality of life
We have observed improved behavior and attention despite
absence of cognitive changes in our cohort. This may be partly
attributable to improved sleep as reported by caregivers for 26 of
our patients. Although sleep was not studied formally in our
cohort, improved daytime sleepiness has been reported by Malow
et al. in 15 subjects treated with VNS and evaluated with multiple
sleep latency tests.20 The review of 687 pediatric patients from the
Cyberonics Patient Outcome registry also showed that alertness
was improved in more than 70% of children at 12 months.21 In a
retrospective review of autistic children treated with VNS, Park
described improvement in alertness in 76% of patients.22 In
addition, quality of life seems to be improved in the vast majority
of patients treatedwith VNS, irrespective of seizure control, andwe
suspect this to be partly attributable to improved sleep.
Despite improvement on seizure frequency, VNS did notmodify
cognitive functions in our patients. This is in line with previous
reports. In a cohort of 160 patients, Dodrill andMorris used various
neuropsychological tests and detected no signiﬁcant difference
between baseline and follow-up cognitive functions.23 Similarly, a
prospective study of 36 adults followed over 6months with formal
neuropsychological testing did not reveal any signiﬁcant change
over time in cognitive performance.24
Conclusion
Our results show that VNS parameters can be increased weekly
leading to an early clinical response, which is sustained at 2 years.
This more aggressive ramping pattern is associated with sig-
niﬁcant improvement at 6 months and even earlier, but should be
limited to children with multiple daily seizures because it also
leads to a higher rate of adverse events. Extra caution must be
exercised in cognitively impaired children as rapidly increasing
parameters might aggravate pre-existing dysphagia.
In addition to seizure improvement, other beneﬁts of VNS in
childhood refractory epilepsy must also be stressed, includ-ing signiﬁcant improvements in alertness, nigh time sleep and
behavior.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.seizure.2008.06.010.
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